Skip to content
Oncology Research Hub

Duarte, California

Cancer clinical trials in Duarte, CA

250 cancer studies are recruiting participants at sites in Duarte as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Duarte at a glance

  • 250 studies are recruiting at a site in Duarte.
  • By phase: Early Phase 1 (2), Phase 1 (75), Phase 1/2 (32), Phase 2 (70), Phase 2/3 (6), Phase 3 (34), Phase 4 (1), No phase (12), Observational (18). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (119), industry (116), government (15).
  • By research area: Lymphoma (109), Breast Cancer (55), Lung Cancer (40), Prostate Cancer (29), Pancreatic Cancer (12), Melanoma (5).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Duarte

Basic details from each study's public record (the 30 most recently updated of 250). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT05894239 · updated
  2. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT03418961 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT06058377 · updated
  4. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    City of Hope
    Registry record
    NCT06638307 · updated
  5. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    City of Hope ( Site 0097)
    Registry record
    NCT06841354 · updated
  6. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT07503808 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Duarte, CA on ClinicalTrials.gov.

Lung cancer studies recruiting in Duarte

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT06287775 · updated
  2. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    City of Hope Cancer Center-Duarte
    Registry record
    NCT07277413 · updated
  3. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    City of Hope-Duarte-56419
    Registry record
    NCT04886804 · updated
  4. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07291037 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Duarte, CA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Duarte

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT04423211 · updated
  2. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    City of Hope National Medical Center
    Registry record
    NCT04221542 · updated
  3. PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT05805371 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Duarte, CA on ClinicalTrials.gov.

Lymphoma studies recruiting in Duarte

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT06724237 · updated
  2. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    City of Hope
    Registry record
    NCT07221500 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    City of Hope Comprehensive Cancer Center ( Site 0191)
    Registry record
    NCT06890884 · updated
  4. Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07109219 · updated
  5. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    City of Hope - Duarte Cancer Center ( Site 1301)
    Registry record
    NCT07634471 · updated
  6. Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT07758673 · updated
  7. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT03739814 · updated
  8. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT04269902 · updated
  9. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT05272384 · updated
  10. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT05675410 · updated
  11. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT06337318 · updated
  12. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT07003295 · updated
  13. Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope Medical Center
    Registry record
    NCT07275216 · updated
  14. Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Memorial Sloan Kettering Cancer Center
    Study site
    City of Hope Cancer Center
    Registry record
    NCT03618550 · updated
  15. BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    PeproMene Bio, Inc.
    Study site
    City of Hope Medical Center
    Registry record
    NCT05370430 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Duarte, CA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Duarte

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US051
    Registry record
    NCT07522073 · updated
  2. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    City of Hope Comprehensive Cancer Center
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Duarte, CA on ClinicalTrials.gov.

Ask about studies near Duarte

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call